New drug duo takes on tough breast cancer
NCT ID NCT07011654
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether combining two drugs, naxitamab and sacituzumab govitecan, is safe and effective for people with metastatic triple-negative breast cancer. The study aims to find the best dose and check for side effects in 31 adults whose cancer has spread. If successful, this could offer a new treatment option for a hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- naxitamab and sacituzumab govitecan
- What this could lead to
- If it works, this could point toward a new combination treatment for metastatic triple-negative breast cancer that may help shrink tumors or slow disease progression.
- What could go wrong
- This is an early-phase trial with only 31 participants, so results may not apply to all patients. The combination may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- New drug targets Hard-to-Treat cancers in japanese patients
- Could a simple capsule beat chemo fatigue? new trial aims to find out
- Experimental cell therapy targets multiple cancers in early trial
- Scientists hunt for clues to better treat aggressive breast cancer
- New pill takes on tough breast cancer in first human trial